Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

TRICAV-II Pivotal: sistema di valvole TRIcvalve biCAVal per grave rigurgito tricuspidale. (TRICAV-II)

12 novembre 2026 aggiornato da: P+F Products + Features USA Inc.

Uno studio clinico prospettico, multicentrico, randomizzato sul sistema di valvole bicavali transcatetere TricValve in soggetti con grave rigurgito tricuspidale (TR).

Pivotal trial to evaluate the safety and effectiveness of the P&F TricValve® Transcatheter Bicaval Valve System.

Panoramica dello studio

Descrizione dettagliata

The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the TricValve System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with severe tricuspid regurgitation and unsuitable for approved transcatheter therapies. Subjects will be followed at discharge, 1 month, 30 days, 3 months, 6 months 12 months, and annually up to 5 years.

Tipo di studio

Interventistico

Iscrizione (Stimato)

780

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233
        • University of Alabama
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85013
        • St. Joseph's Hospital and Medical Center
    • California
      • Sacramento, California, Stati Uniti, 95817
        • UC Davis Health
      • San Diego, California, Stati Uniti, 92037
        • Scripps Memorial Hospital La Jolla
      • San Francisco, California, Stati Uniti, 94143
        • UCSF
      • San Jose, California, Stati Uniti, 94118
        • Kaiser Permanente
        • Investigatore principale:
          • Andrew Rassi, MD
        • Contatto:
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • MedStar Washington Hospital Center (MWHC)
        • Contatto:
          • Erin Collins
        • Investigatore principale:
          • Toby Rogers, MD
    • Florida
      • Delray Beach, Florida, Stati Uniti, 33484
        • Delray Medical Center
      • Largo, Florida, Stati Uniti, 33770
      • Tampa, Florida, Stati Uniti, 33606
        • Tampa General Hospital
    • Illinois
      • Glenview, Illinois, Stati Uniti, 60026
        • Endeavor Health
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46260
        • Ascension Medical Group St. Vincent The Heart Center of Indiana
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66103
        • University of Kansas Medical Center
    • Louisiana
      • Houma, Louisiana, Stati Uniti, 70360
        • Cardiovascular Institute of the South
        • Investigatore principale:
          • Peter Fail, MD
        • Contatto:
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Stati Uniti, 02114
        • Massachusetts General Hospital
      • Burlington, Massachusetts, Stati Uniti, 01805
        • Lahey Hospital & Medical Center
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti, 55407
        • Minneapolis Heart Institute Foundation
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64111
        • Saint Luke's Mid America Heart Institute
      • St Louis, Missouri, Stati Uniti, 63110
        • Washington University of St Louis
    • New Jersey
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Hackensack University Medical Center
    • New York
      • Manhasset, New York, Stati Uniti, 11030
        • Northwell Hospital
      • The Bronx, New York, Stati Uniti, 10467
        • Montefiore Medical Center
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44106
        • Cleveland Clinic
        • Investigatore principale:
          • Rishi Puri, MD
      • Columbus, Ohio, Stati Uniti, 43214
        • Riverside Methodist Hospital
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Oregon Health
        • Investigatore principale:
          • Firas Zahr, MD
        • Contatto:
    • South Carolina
      • Charleston, South Carolina, Stati Uniti, 29425
        • MUSC
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Houston Methodist
      • Houston, Texas, Stati Uniti, 77030
        • University of Texas (Memorial Hermann)
      • Plano, Texas, Stati Uniti, 75093
        • Baylor Scott & White Medical
    • Utah
      • Murray, Utah, Stati Uniti, 84107
        • Intermountain Heart Institute - Intermountain Medical Center
        • Investigatore principale:
          • Brian Whisenant, MD
        • Contatto:
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22903
        • UVA School of Medicine
      • Norfolk, Virginia, Stati Uniti, 23507
        • Sentara Healthcare
      • Roanoke, Virginia, Stati Uniti, 24014
        • Carilion Clinic

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 85 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Eligibility Criteria for Randomized Cohort:

Inclusion Criteria:

  1. Age between 18 years and 85 years old, at the time of signing the informed consent.
  2. Severe tricuspid regurgitation (TR) and Caval Reflux (CR), as determined by the qualifying transthoracic echocardiogram (TTE) confirmed by an echocardiography Core Lab. TVARC criteria will be used for the definition of TR severity.
  3. NYHA Class II-III-IVa (not on inotropes, IABP or LVAD) or heart failure (HF) admission in the past 6 months.
  4. Adequately treated with optimal medical therapy (OMT) for heart failure per the local Heart Team at the time of TR assessment for eligibility (TTE). OMT includes stable oral diuretic medications.
  5. High risk for open surgery and is appropriate for transcatheter tricuspid therapies according to the local heart team.
  6. Patient is unsuitable for approved transcatheter therapies and is eligible for the TricValve procedure, based on review of screening/baseline data and imaging core lab measurements by Central Screening Committee.
  7. For females of childbearing potential, negative pregnancy test.
  8. Capable and willing to provide signed informed consent

Exclusion Criteria:

CONCOMITANT PROCEDURES

  1. Patient had a recent MI, stroke, or cardiovascular accident; underwent coronary artery bypass graft surgery, had a percutaneous coronary intervention or other major cardiovascular surgery within 90 days prior to TricValve implantation.

  2. Patient requires another planned major cardiac procedure, including left-sided transcatheter intervention or surgery (e.g. severe aortic stenosis, severe mitral regurgitation), coronary artery bypass or PCI or pulmonary valve correction.

    CARDIOVASCULAR CONDITIONS

  3. LVEF ≤ 30% on echocardiography.

  4. Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.

  5. Severe right ventricular dysfunction.

  6. Cardiac amyloidosis.

  7. Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or right heart catheterization.

  8. Lower extremity venous thrombosis and/or the presence of an IVC filter at the time of or 6 months prior to the TricValve procedure.

  9. Hemodynamically significant pericardial effusion.

  10. Hemodynamic instability, cardiogenic shock, inotropic support, intra-aortic balloon pump or acute heart failure within 30 days prior to the TricValve procedure.

  11. Patient with refractory heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) (ACC/ AHA/ ESC/ EACTS Stage D heart failure).

  12. Presence of significant congenital or acquired heart disease such as RV dysplasia, arrhythmogenic RV or other conditions that could interfere with the TricValve procedure.

    ALLERGIES / INTOLERANCE

  13. Any known allergy or hypersensitivity to nitinol, bovine tissue, or contrast media that cannot be adequately treated with pre-medication.

  14. Unable to tolerate anticoagulation/antiplatelet therapy

    COMORBIDITIES

  15. Any known life-threatening condition with an estimated life span of less than 12 months.

  16. Platelet count < 75,000/mm3

  17. Child-Pugh Severity Class C (10-15 points).

  18. Severe renal insufficiency with estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2 or requiring chronic renal replacement therapy at the time of enrollment.

  19. Endocarditis or active/ongoing infection requiring antibiotics.

  20. Unable to walk at least 100 meters in a 6-minute walk test.

  21. Known bleeding or clotting disorders or patient refuses blood transfusion.

  22. Active gastrointestinal (GI) bleeding within 3 months of TricValve procedure.

  23. Prior Malignancy: this study excludes participants at material risk of near-term cancer-related morbidity/mortality that could confound 12-month outcomes. This study allows the inclusion of fully treated, remote malignancies with documented No Evidence of Disease (NED)" criteria

    a. History of any malignancy within 5 years prior to randomization or any active malignancy, except: i. Adequately treated non-melanoma skin cancer (basal or squamous cell) with no evidence of disease, or ii. Carcinoma in situ (e.g., cervical, breast DCIS) treated with curative intent and no evidence of disease.

    b. Participants with a prior malignancy diagnosed >5 years before randomization are eligible if they meet all of the "No Evidence of Disease (NED)" criteria as specified below: i. No signs/symptoms of cancer on history and physical exam per standard of care; ii. No radiologic evidence of disease on surveillance imaging if such imaging is routinely indicated for that tumor type (not protocol-mandated); iii. Tumor markers (if applicable for that cancer) not suggestive of recurrence (e.g., stable/undetectable within site's lab reference and oncologist's judgment); iv. No active anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy, radiotherapy) and none planned; v. Treating oncologist's attestation (or primary physician if oncology follow-up is complete) that the participant is disease-free and appropriate for participation.

    GENERAL EXCLUSIONS

  24. Use or participation in other investigational device or drug study in which the patient has not reached a primary endpoint to treat cardiovascular conditions related to the outcomes of the current study.

  25. Any other condition that would preclude the ability to meet study requirements in the opinion of the investigator.

  26. Psychiatric/behavioral issues or other medical or social conditions that preclude valid consent and follow-up

  27. Pregnant or breastfeeding subjects and those who plan pregnancy during the clinical investigation follow-up period.

Eligibility Criteria for Single Arm Cohort:

Inclusion Criteria:

  1. Age > 85 years.
  2. NYHA Class III-IV, on intravenous inotropes, IABP or LVAD.
  3. LVEF ≤ 30% on echocardiography.
  4. Severe RV dysfunction.
  5. Severe pulmonary hypertension (PH), defined as Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or mean Pulmonary Artery Pressure (mPAP >35) by right heart catheterization.
  6. Renal insufficiency: eGFR between 25 and 30 mL/min/ 1.73 m² or on chronic renal replacement therapy.
  7. Patient unable to walk a minimum distance of 100 mt during 6 minute walk test.
  8. Prior malignancy not meeting the requirements applied for the Randomized Cohort, specified in Exclusion Criterion #23.
  9. Comorbidities precluding inclusion in the Randomized Cohort (exclusion criteria #15 to #24).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: TricValve System + Optimal medical therapy (OMT)

Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy (OMT) in patients with caval reflux and tricuspid regurgitation.

• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy

Altri nomi:
  • Heterotopic caval valve implantation (CAVI)

Optimal medical therapy

Altri nomi:
  • OMT
Comparatore attivo: Optimal medical therapy (OMT) Alone

OMT alone in patients with caval reflux and tricuspid regurgitation

Optimal medical therapy

Altri nomi:
  • OMT
Sperimentale: TricValve Single Arm Registry

Single-Arm Registry for Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with OMT in patients with caval reflux and tricuspid regurgitation who are not eligible for randomization

• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy

Altri nomi:
  • Heterotopic caval valve implantation (CAVI)

Optimal medical therapy

Altri nomi:
  • OMT

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Randomized Cohort: Caval Reflux (CR) grade reduction
Lasso di tempo: 6 months

Reduction in Caval Reflux (CR) assessed by the echocardiography core laboratory. The CR will be assessed using the 3-grade scale: Grade 1 (no reflux, reflux extending for less than 1 cm below the diaphragm), Grade 2 ( reflux extending for less than 3 cm), Grade 3 (reflux of 3 cm or more). Lower grades of CR are better.

6 months
Randomized Cohort: Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement
Lasso di tempo: 6 months

Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm.

6 months
Randomized Cohort: Rate of Major Adverse Events (MAE)
Lasso di tempo: 30 days

Rate of Major Adverse Events (MAE) in experimental arm (TricValve + OMT)

30 days
Randomized Cohort: Hierarchical composite endpoint: all-cause mortality, RVAD implantation or heart transplant, tricuspid valve surgery or percutaneous tricuspid intervention, heart failure hospitalizations, KCCQ improvement, NYHA functional class improv
Lasso di tempo: 1 year

Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm.

1 year
Registry Cohort: Rate of Major Adverse Events (MAE)
Lasso di tempo: 30 days

Rate of Major Adverse Events (MAE) in single arm registry

30 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Randomized Cohort: Percentage of Device- and/or Procedure-related MAEs
Lasso di tempo: 1 year

Rate of Major Adverse Events

1 year
Randomized Cohort: All-Cause mortality and Cardiovascular Mortality
Lasso di tempo: 6 months and 1 year

Number of deaths from any cause as well as cardiovascular events

6 months and 1 year
Randomized Cohort: Heart Failure Hospitalizations (HFH)
Lasso di tempo: 6 months and 1 year

Number of Heart Failure Hospitalizations and worsening HF events without hospitilization

6 months and 1 year
Randomized Cohort: RVAD Implantation or Heart Transplant
Lasso di tempo: 6 months and 1 year

Number of patients requiring RVAD Implantation or Heart Transplant

6 months and 1 year
Randomized Cohort: Atrial Fibrillation
Lasso di tempo: 1 year

New onset of atrial fibrillation

1 year
Randomized Cohort: Quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) .
Lasso di tempo: 6 months and 1 year

Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL)

6 months and 1 year
Randomized Cohort: Changes in symptom status New York Heart Association (NYHA class)
Lasso di tempo: 6 months and 1 year

Reduction of at least 1 class from baseline. The NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

6 months and 1 year
Randomized Cohort: Changes in functional capacity (6-minute walk test, 6MWT).
Lasso di tempo: 6 months and 1 year

Improvement of 6-minute walk distance of at least 30 meters from baseline.

6 months and 1 year
Registry Cohort: Heart Failure Hospitalization
Lasso di tempo: 1 year

Comparison of the 12-month post-procedure HFH rate with the 12-month pre-procedure rate

1 year
Registry Cohort: Changes in Quality of life (by Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score).
Lasso di tempo: 1 year

Change from baseline to 12 months. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL)

1 year
Roll-In Cohort: Percentage of Device- and/or Procedure-related MAEs
Lasso di tempo: 1 year

Rate of Major Adverse Events

1 year
Roll-In Cohort: All-Cause mortality and Cardiovascular Mortality
Lasso di tempo: 6 months and 1 year

Number of deaths from any cause as well as cardiovascular events

6 months and 1 year
Roll-In Cohort: Heart Failure Hospitalizations (HFH)
Lasso di tempo: 6 months and 1 year

Number of Heart Failure Hospitalizations and worsening HF events without hospitalization

6 months and 1 year
Roll-In Cohort: RVAD Implantation or Heart Transplant
Lasso di tempo: 6 months and 1 year

Number of patients requiring RVAD Implantation or Heart Transplant

6 months and 1 year
Roll-In Cohort: Atrial Fibrillation
Lasso di tempo: 1 year

New onset of atrial fibrillation

1 year
Roll-In Cohort: Quality of life as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ).
Lasso di tempo: 6 months and 1 year

Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life

6 months and 1 year
Roll-In Cohort: New York Heart Association (NYHA) functional class
Lasso di tempo: 6 months and 1 year

Reduction of at least 1 class from baseline. NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

6 months and 1 year
Roll-In Cohort: 6-minute walk test (6MWT).
Lasso di tempo: 6 months and 1 year

Improvement of 6-minute walk distance of at least 30 meters from baseline.

6 months and 1 year

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 novembre 2028

Completamento dello studio (Stimato)

1 novembre 2032

Date di iscrizione allo studio

Primo inviato

7 giugno 2024

Primo inviato che soddisfa i criteri di controllo qualità

12 giugno 2024

Primo Inserito (Effettivo)

14 giugno 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CTP-TRIC-005-II

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi